drugset / Trial / NCT05300958
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
Timeline
- Start
- 2022-03-21
- Primary completion
- 2025-07-21
- Completion
- 2025-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferoxamine | Other / unclassified | 50 mg/kg | — |